'Shedding' light on mechanisms of hyperphosphatemic vascular dysfunction.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 23364583.
- Also identified by DOI 10.1038/ki.2012.416.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cardiovascular disease is prevalent in chronic kidney disease (CKD) populations. Vascular dysfunction characterized by endothelial-cell damage, inflammation, and impaired angiogenesis is described in CKD, and hyperphosphatemia has been associated with vascular disease in CKD and general populations. We discuss the findings of elegant studies by Di Marco et al., linking hyperphosphatemia to downregulation of annexin II, an important protein implicated in fibrinolysis, cell adhesion, signal transduction, and angiogenesis.
Medical subject headings
- Annexin A2
- Hyperphosphatemia